Mycoplasma Pneumoniae Infection: Symptoms And Treatment Guide
Comprehensive guide to Mycoplasma pneumoniae: symptoms, skin manifestations, diagnosis, and management strategies.
Mycoplasma pneumoniae is a significant bacterial pathogen responsible for atypical or “walking” pneumonia, particularly in community settings. This infection, caused by a wall-less bacterium, not only affects the respiratory tract but also manifests in various extrapulmonary sites, including the skin, making it relevant in dermatological practice. Unlike typical bacteria, M. pneumoniae lacks a cell wall, rendering it resistant to beta-lactam antibiotics and allowing it to evade host defenses through cytoadherence and intracellular persistence. Outbreaks often occur in crowded environments like schools and families, with an incubation period of 1-4 weeks.
What is Mycoplasma pneumoniae?
Mycoplasma pneumoniae belongs to the class Mollicutes, characterized by its small size (1-2 μm long by 0.1-0.2 μm wide), pleomorphic spindle shape, and absence of a peptidoglycan cell wall. This unique structure enables it to form “fried egg” colonies on agar plates, rarely exceeding 100 μm in diameter. As an obligate parasite, it relies on host cells for nutrients, adhering via a specialized polar attachment organelle that facilitates motility, invasion, and evasion of the immune system. The bacterium produces toxins like CARDS toxin and hydrogen sulfide, contributing to cytotoxicity, inflammation, and symptoms such as persistent cough and lung irritation. Its genome is reduced, limiting metabolic pathways and promoting persistence even post-treatment.
Who gets Mycoplasma pneumoniae infection?
Infections predominantly affect children and young adults aged 5-20 years, with peak incidence in school-aged populations due to close contact in crowded settings. Herd immunity wanes after 2-10 years (typically 4 years), allowing reinfections. Vulnerable groups include those with hypogammaglobulinemia, sickle cell disease, or underlying respiratory conditions like asthma and COPD, where M. pneumoniae exacerbates symptoms. Transmission occurs via respiratory droplets from coughing, sneezing, or talking, with prolonged outbreaks due to the 2-4 week incubation and persistent shedding. Family clusters and institutional outbreaks are common.
What causes infection with Mycoplasma pneumoniae?
The primary cause is inhalation of aerosolized respiratory droplets containing M. pneumoniae from infected individuals. The bacterium targets respiratory epithelium, using its attachment organelle for cytoadherence, followed by fusion with host cells for intracellular survival. This evades immune detection and antibiotics. Pathogenic mechanisms include toxin release (e.g., hydrogen peroxide, hydrogen sulfide), cytokine induction via Toll-like receptors (TLR1, TLR2, TLR6, TLR4), and disruption of ciliated epithelium, leading to ciliostasis, cell shedding, and inflammation. Immune hyperactivity contributes to extrapulmonary complications.
What are the clinical features of Mycoplasma pneumoniae infection?
Most cases present as mild, self-limited respiratory illness (pharyngitis, tracheobronchitis), with only 3-13% progressing to pneumonia. Symptoms develop insidiously over 3-5 days: persistent dry cough (hallmark), fever (96-100%), malaise, headache, sore throat, nasal symptoms (29-69%), myalgias (45%), and auscultatory findings like rales/wheezes (80-84%). Pneumonia features patchy infiltrates on chest X-ray despite minimal physical signs. Extrapulmonary manifestations occur in 25%, including dermatological (vesicles, maculopapular rash, erythema multiforme, Stevens-Johnson syndrome), hemolytic anemia, neurological (encephalitis, Guillain-Barré), and gastrointestinal issues. Skin lesions, often vesicular or target-like, appear early and may precede respiratory symptoms.
| Sign/Symptom | Frequency (%) |
|---|---|
| Fever | 96–100 |
| Rales, wheezes | 80–84 |
| Nasal symptoms | 29–69 |
| Myalgias | 45 |
| Pharyngeal erythema | 12–73 |
| Cervical adenopathy | 18–27 |
Diagnosis of Mycoplasma pneumoniae infection
Diagnosis combines clinical suspicion (stubborn cough, fever, normal WBC <10,000/μL, minor disease absence) with tests. Chest X-ray shows interstitial or patchy infiltrates. PCR from throat swabs or sputum is gold standard (high sensitivity/specificity). Serology detects IgM (acute) and IgG rise (fourfold in paired sera). Culture is impractical due to slow growth. Discriminate criteria: ≥4 factors (e.g., cough, auscultation abnormalities, low WBC) yield 88.7% sensitivity, 77.5% specificity. Extrapulmonary clues include cold agglutinins (hemolytic anemia) and skin biopsy for interface dermatitis in eruptions.
How is Mycoplasma pneumoniae infection treated?
Macrolides (azithromycin, clarithromycin) are first-line due to cell wall absence; alternatives include tetracyclines (doxycycline) or fluoroquinolones (levofloxacin) for resistance. Treatment shortens symptoms and reduces contagion, especially in outbreaks. Supportive care: hydration, antipyretics, cough suppressants. Severe cases or complications (e.g., SJS) require hospitalization, IV antibiotics, and steroids. Resistance to macrolides is rising (up to 10% in some regions), necessitating susceptibility testing. Most resolve in 7-14 days, but cough persists weeks.
Complications of Mycoplasma pneumoniae infection
Respiratory: prolonged cough, asthma exacerbation, bronchiolitis obliterans. Extrapulmonary: Stevens-Johnson syndrome/toxic epidermal necrolysis (rare, fatal), encephalitis, myelitis, Guillain-Barré syndrome, hemolytic anemia (cold agglutinins), cardiac (myocarditis, pericarditis), renal dysfunction, arthritis. Dermatological complications include vesicular eruptions, urticaria, and erythema nodosum. Severity links to immune response; immunocompromised patients face worse outcomes. Fatalities are rare (<1%), mainly in extremes of age or comorbidities.
What is the outcome for Mycoplasma pneumoniae infection?
Prognosis is excellent; most recover fully within weeks with supportive care. Cough may linger 1-2 months. Reinfections occur due to partial immunity. Long-term sequelae include reactive airway disease or asthma worsening in predisposed individuals. Early antibiotics prevent complications in high-risk groups. Public health surveillance aids outbreak control.
How can Mycoplasma pneumoniae infection be prevented?
No vaccine exists. Prevention relies on hygiene: handwashing, covering coughs, avoiding close contact with symptomatic persons. Isolate cases in outbreaks (schools, households). Prophylactic antibiotics not routine. Education on droplet precautions curbs spread, especially in crowded settings.
Related topics
- Atypical pneumonia
- Community-acquired pneumonia
- Erythema multiforme
- Stevens-Johnson syndrome
- Walking pneumonia
Frequently Asked Questions
Q: What is walking pneumonia?
A: Walking pneumonia is a mild form of Mycoplasma pneumoniae infection with symptoms like cough and fever allowing daily activities, unlike severe bacterial pneumonia.
Q: How long does Mycoplasma pneumoniae last?
A: Symptoms typically resolve in 1-2 weeks with treatment, but cough can persist up to 4-6 weeks.
Q: Is Mycoplasma pneumoniae contagious?
A: Yes, via respiratory droplets; contagious during symptomatic phase and up to 1-2 weeks after.
Q: Can Mycoplasma pneumoniae cause skin rashes?
A: Yes, in 10-25% of cases, presenting as maculopapular, vesicular, or target lesions like erythema multiforme.
Q: When should antibiotics be used for Mycoplasma?
A: For pneumonia, prolonged symptoms, or high-risk patients; macrolides preferred.
References
- Mycoplasma pneumoniae – Wikipedia — Wikipedia. 2023-10-01. https://en.wikipedia.org/wiki/Mycoplasma_pneumoniae
- Mycoplasma pneumoniae infection: Basics – PMC — PubMed Central (PMC). 2017-11-01. https://pmc.ncbi.nlm.nih.gov/articles/PMC5689399/
- Mycoplasma Pneumoniae: Overview of the Outbreak — Pediatric Pandemic Network. 2023-01-01. https://pedspandemicnetwork.org/news/mycoplasma-pneumoniae-overview-of-the-outbreak/
- Mycoplasma pneumoniae Infectious Substances Pathogen Safety — Government of Canada (Public Health Agency). 2022-01-01. https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/mycoplasma-pneumoniae.html
- Mycoplasma Pneumonia | Diagnosis & Disease Information — Infectious Disease Advisor. 2024-01-01. https://www.infectiousdiseaseadvisor.com/ddi/mycoplasma-pneumonia/
- A Compendium for Mycoplasma pneumoniae — Frontiers in Microbiology. 2016-04-01. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2016.00513/full
- About Mycoplasma pneumoniae Infection – CDC — Centers for Disease Control and Prevention (CDC). 2023-01-01. https://www.cdc.gov/mycoplasma/about/index.html
Similar Articles
Read full bio of Sneha Tete
